AI assistant
IMUGENE LIMITED — Capital/Financing Update 2013
Nov 3, 2013
65124_rns_2013-11-03_886ef661-e14f-42b6-af10-9f01eeba9a83.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [227 x 49] intentionally omitted <==
Private
Placement
Melbourne, 4 November 2013. On 23 October 2013, Imugene Limited (Company) announced a private placement of 250,000,000 ordinary shares in the Company (Shares) at $0.01 per Share to sophisticated investors and clients of Forrest Capital to raise $2,500,000. The Company confirms the issue and allotment of the first tranche of 85,000,000 placement Shares raising $850,000. The remaining 165,000,000 Shares will be issued subject to shareholder approval at a soon to be convened EGM.
Of the 85,000,000 Shares issued, 47,747,385 Shares were issued pursuant to ASX Listing Rule 7.1 and 37,252,615 were issued pursuant to ASX Listing Rule 7.1A. An Appendix 3B in regards to the issue of 85,000,000 Shares was lodged with ASX on 31 October 2013.
In accordance with ASX Listing Rule 3.10.5A the following information is provided to the ASX in relation to the issue of 37,252,615 Shares pursuant to ASX Listing Rule 7.1A.
-
The issue of 37,252,615 Shares pursuant to ASX Listing Rule 7.1A raised $372,526 and diluted the voting power of existing shareholders by 8.01%.
-
Imugene elected to issue the Shares as a placement under Listing Rule 7.1A rather than a pro rata issue (or other type of issue) due to the strong support from sophisticated investors and the cost and timing benefits of a private placement.
-
There were no underwriting agreements in connection with the issue.
-
The Company incurred a broker commission fee equal to 6% of funds raised.
For more information please visit www.imugene.com
Ends
Investor contact:
Dr Nick Ede, Imugene – +61 400 642 254 / [email protected]
About Imugene
Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.
Imugene Limited A.C.N: 009 179 551 Suite 1, 1233 High Street, Armadale, VIC, 3142 Phone: 03 9824 5254 Fax: 03 9822 7735